Form 8-K · Current report
Edwards Lifesciences 8-K, filed Nov 4, 2026
- Filed
- CIK
- 0001099800
- Accession no.
- 0001099800-26-000053
Summary
Edwards Lifesciences reported third-quarter 2026 sales of $1.72 billion, up 10.5% year over year, and raised its full-year 2026 sales and adjusted EPS guidance. The company said TAVR sales grew 8.0% and TMTT sales grew 44.0%, and it highlighted recent product approvals and clinical trial results in structural heart therapies.
Key points
- Edwards Lifesciences reported Q3 2026 sales of $1.72 billion, up 10.5% year over year, and constant-currency growth of 11.2%.
- TAVR sales rose 8.0% to $1.24 billion, while TMTT sales rose 44.0% to $207 million.
- Adjusted EPS was $0.80, up 19% from a year earlier, and the company raised its 2026 sales and adjusted EPS guidance.
- The company highlighted the PROGRESS trial in moderate aortic stenosis published in NEJM and FDA approvals for PASCAL Precision for tricuspid repair and PASCAL Ace with Capture Clarity for mitral TEER.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. On November 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the third quarter of 2026. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended. Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press release, dated November 4, 2026, reporting Edwards’ financial results for the third quarter of 2026. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.